|
|
|
|
|
|
|
OMB APPROVAL |
|
|
OMB Number: |
|
3235-0080 |
|
|
Expires: |
|
May 31, 2027 |
|
|
Estimated average burden hours per response: |
|
1.00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING
AND/OR REGISTRATION UNDER SECTION 12(b)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-40227
Finch Therapeutics Group, Inc.
The Nasdaq Global Select Market
(Exact name of Issuer as specified in its charter, and name of Exchange
where security is listed and/or registered)
75 State
Street, Suite 100
Boston, MA 02109 (617) 229-6499
(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
Common Stock, $0.001 par value per share
(Description of class of securities)
Please place an X in the box to
designate the rule provision relied upon to strike the class of securities from listing and registration:
| |
☐ |
17 CFR 240.12d2-2(a)(1) |
| |
☐ |
17 CFR 240.12d2-2(a)(2) |
| |
☐ |
17 CFR 240.12d2-2(a)(3) |
| |
☐ |
17 CFR 240.12d2-2(a)(4) |
| |
☐ |
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its
rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1 |
| |
☒ |
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the
rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange. |
Pursuant to the requirements of the Securities Exchange Act of 1934, Finch Therapeutics Group, Inc. certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
| October 31, 2024 |
|
|
|
By: |
|
/s/ Matthew P. Blischak |
|
|
|
Chief Executive Officer |
| Date |
|
|
|
Name: |
|
Matthew P. Blischak |
|
|
|
Title |
| 1 |
Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions. |
|
|
|
| SEC 1654 (03-06) |
|
Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number. |